IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Britta HARDY et al.	Confirmation No.: 9624
Patent No.: 7,122,372 B2	Application No.: 10/821,283
Patent Date: October 17, 2006	Filing Date: April 9, 2004
For: PEPTIDE USEFUL IN IMMUNOMODULATION	Attorney Docket No.: 85189-6100

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 C.F.R. § 1.322

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Patentees hereby respectfully request the issuance of a Certificate of Correction in connection with the above-identified patent. The corrections are listed on the attached Form PTO-1050. The corrections requested are as follows:

Column 37:

Line 16 (claim 1, line 5), before "11 through 16;" change "NOs;" to -- NOs: --. Support for this change appears in the Examiner's Amendment attached to the Supplemental Notice of Allowability mailed February 10, 2006.

Line 18 (claim 1, line 7), before "(a);" change "as" to -- of --. Support for this change appears in application claim 1.

Line 45 (claim 9, line 2), after "comprising the step of" change "administerin" to -- administering --. Support for this change appears in new application claim 40 of the Examiner's Amendment attached to the Supplemental Notice of Allowability mailed February 10, 2006.

Column 38:

Line 56 (claim 29, line 1), after "A host cell comprising a vector according to claim" delete "**17**" and insert -- **27** --. Support for this change appears in new application claim 38 of the Examiner's Amendment attached to the Supplemental Notice of Allowability mailed February 10, 2006.

The requested corrections are for errors that appear to have been made by the Office. Therefore, no fee is believed to be due for this request. Should any fees be required, however, please charge such fees to Winston & Strawn LLP Deposit Account No. 50-1814. Please issue a Certificate of Correction in due course.

Respectfully submitted,

10/31/06

Date

Allan A. Fanucci, Reg. No. 30,256

WINSTON & STRAWN LLP
Customer No. 28765

212-294-3311

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO.: 7,122,372 B2
APPLICATION NO.: 10/821,283
DATED: Oct. 17, 2006
INVENTOR(S): Hardy et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 37:
Line 16, before "11 through 16;" change "NOs;" to -- NOs: --.
Line 18, before "(a);" change "as" to -- of --.
Line 45, after "comprising the step of" change "administerin" -- administering --.

Column 38:
Line 56, after "A host cell comprising a vector according to claim" delete "**17**" and insert -- **27** --.

WINSTON & STRAWN LLP
Patent Department
1700 K Street, N.W.
Washington, D.C. 20006-3817

-continued

<223> OTHER INFORMATION: nucleotide encoding peptide recognized by the BAT-1 monoclonal antibody

<400> SEQUENCE: 33

aaccgaatca ggacaaatac taagctcatg aacagc 36

What is claimed is:

1. An isolated peptide comprising at least one epitope that is recognized by and binds to a BAT monoclonal antibody, said peptide selected from the group consisting of:
(a) a peptide having the sequence of any one of SEQ ID NOs; 11 through 16;
(b) a peptide having at least 70% identity with a peptide as (a);
(c) a fragment of a peptide of (a) or (b); and
(d) a combination of peptides according to (a), (b), or (c).

2. The peptide according to claim 1, wherein said peptide is selected from the group consisting of:
(a) a peptide having the sequence of any one of SEQ ID NOs: 14 or 16;
(b) a peptide having at least 70% identity with a pepetid of (a);
(c) a fragment of a peptide of (a) or (b); and
(d) a combination of peptides according to (a), (b), or (c).

3. The peptide according to claim 1, wherein said peptide is capable of inhibiting binding of BAT monoclonal antibody to lymphoma cells.

4. The peptide according to claim 3, wherein the lymphone cells are Daudi or Jurkat cells.

5. An immunomodulatory vaccine comprising at least one epitope according to claim 1.

6. The vaccine according to claim 5, wherein the adjuvant is selected from the group consisting of an aluminum salt and an oil in water emulsion.

7. A diagnostic agent for detecting cancer comprising at least one epitope according to claim 1.

8. A composition comprising as an active ingredient at least one epitope according to claim 1 and a pharmaceutically acceptable carrier.

9. A method for treating cancer in a subject in need thereof comprising the step of administerin a therapeutically effective amount of a composition according to claim 8.

10. An isolated polynucleotide encoding at least one epitope according to claim 1.

11. The vector according to claim 10 wherein the polynucleotide comprises a sequence selected from SEQ ID NOs: 26 through 31.

12. The vector according to claim 10 wherein the polynucleotide comprises a sequence selected from SEQ ID NOs: 29 and 31.

13. A vector comprising the polynucleotide according to claim 10.

14. The vector according to claim 13 wherein the vector is a plasmid or a virus.

15. A host cell comprising the vector of claim 13.

16. An isolated peptide capable of inhibiting tumor growth, said peptide selected from the group consisting of:
(a) a peptide having the sequence of any one of SEQ ID NOs: 11 through 16;
(b) a peptide having at least 70% identity with a peptide of (a);
(c) a fragment of a peptide of (a) or (b); and
(d) a combination of peptides according to (a), (b), or (c).

17. The peptide according to claim 16 wherein the peptide is selected from the group consisting of:
(a) a peptide having the sequence of any one of SEQ ID NOs: 14 or 16;
(b) a peptide having at least 70% identity with a peptide of (a);
(c) a fragment of a peptide of (a) or (b); and
(d) a combination of peptides according to (a), (b), or (c).

18. An immunomodulatory vaccine comprising at least one peptide according to claim 16 and a pharmaceutically acceptable adjuvant.

19. The vaccine according to claim 18 wherein the adjuvant is selected from the group consisting of an aluminum salt and an oil in water emulsion.

20. A diagnostic agent for detecting cancer comprising a peptide according to claim 16.

21. A composition comprising as an active ingredient at least one peptide according to claim 16 and a pharmaceutically acceptable carrier.

22. A method for treating cancer in a subject in need thereof comprising the step of administering a therapeutically effective amount of a composition according to claim 21.

23. An isolated polynucleotide encoding at least one peptide according to claim 16.

24. The polynucleotide according to claim 23 said polynucleotide having a sequence selected from the group consisting of SEQ ID NOs: 26 through 31.

25. The polynucleotide according to claim 23 said polynucleotide having a sequence selected from the group consisting of SEQ ID NOs: 29 and 31.

26. A composition comprising as an active ingredient a polynucleotide according to claim 23.

27. A vector comprising the polynucleotide of claim 23.

28. The vector according to claim 27 wherein the vector is a plasmid or a virus.

29. A host cell comprising a vector according to claim 17.

* * * * *

NOs: — NOs;
of — as
administering
27